AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next
AbbVie shares traded near $228.62 Tuesday afternoon, up 0.31%, as investors weighed new pipeline updates and continued debate over U.S. drug pricing. PharmaVoice reported AbbVie is advancing two next-generation neurotoxins, AGN-151607 and TrenibotE, for both aesthetic and therapeutic uses. Nasdaq highlighted strong Skyrizi and Rinvoq sales, projecting over $25 billion combined in 2025.